James Sapirstein, CEO, Therapeutics Division at Adynxx, holds 35.82K shares in Entero Therapeutics (Ticker: ENTO), holds 6.36K shares in Onconetix (Ticker: ONCO), holds 492.82K shares in Hepion Pharmaceuticals (Ticker: HEPA). Most recently, James Sapirstein Sold ― shares of Entero Therapeutics on Jul 03, 2024 for an estimated value of 1.38K.
What is the percentage of profitable transactions made by James Sapirstein?
The percentage of profitable transactions made by James Sapirstein is 86%.
What is the average return per transaction made by James Sapirstein?
The average return per transaction made by James Sapirstein is 69.00%.
What stocks does James Sapirstein hold?
James Sapirstein holds: ADYX, HEPA, RENB, ENTO, MRZM, ONCO stocks.
What was James Sapirstein’s latest transaction?
James Sapirstein latest transaction was an Informative Sell of $1.38K.
What was James Sapirstein's most profitable transaction?
James Sapirstein’s most profitable transaction was an Informative Sell of ENTO stock on July 5, 2023. The return on the trade was 96.40%.
What is James Sapirstein's role in Adynxx?
James Sapirstein's role in Adynxx is CEO, Therapeutics Division.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.